173 related articles for article (PubMed ID: 25566809)
1. Discrepant salivary gland response after radioiodine and MIBG therapies.
Jentzen W; Richter M; Poeppel TD; Schmitz J; Brandau W; Bockisch A; Binse I
Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):331-339. PubMed ID: 25566809
[TBL] [Abstract][Full Text] [Related]
2. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.
Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A
Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767
[TBL] [Abstract][Full Text] [Related]
3. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.
Jentzen W; Balschuweit D; Schmitz J; Freudenberg L; Eising E; Hilbel T; Bockisch A; Stahl A
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2298-306. PubMed ID: 20625723
[TBL] [Abstract][Full Text] [Related]
4. Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET/CT imaging.
Jentzen W; Richter M; Nagarajah J; Poeppel TD; Brandau W; Dawes C; Bockisch A; Binse I
EJNMMI Phys; 2014 Dec; 1(1):100. PubMed ID: 26501458
[TBL] [Abstract][Full Text] [Related]
5. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
[TBL] [Abstract][Full Text] [Related]
6. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
[TBL] [Abstract][Full Text] [Related]
7. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebo-controlled study in patients with differentiated thyroid cancer.
Bohuslavizki KH; Klutmann S; Brenner W; Kröger S; Buchert R; Bleckmann C; Mester J; Henze E; Clausen M
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():6-12. PubMed ID: 10584133
[TBL] [Abstract][Full Text] [Related]
8. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.
Hobbs RF; Jentzen W; Bockisch A; Sgouros G
Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):79-91. PubMed ID: 23474639
[TBL] [Abstract][Full Text] [Related]
9. Thyroidal uptake and radiation dose after repetitive I-131-MIBG treatments: influence of potassium iodide for thyroid blocking.
Brans B; Monsieurs M; Laureys G; Kaufman JM; Thierens H; Dierckx RA
Med Pediatr Oncol; 2002 Jan; 38(1):41-6. PubMed ID: 11835235
[TBL] [Abstract][Full Text] [Related]
10. [Quantitative salivary gland scintigraphy--a recommended examination prior to and after radioiodine therapy].
Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Kalina S; Clausen M; Henze E
Nuklearmedizin; 1997 Apr; 36(3):103-9. PubMed ID: 9162904
[TBL] [Abstract][Full Text] [Related]
11. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E
J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
[TBL] [Abstract][Full Text] [Related]
12. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.
Lee CL; Wahnishe H; Sayre GA; Cho HM; Kim HJ; Hernandez-Pampaloni M; Hawkins RA; Dannoon SF; VanBrocklin HF; Itsara M; Weiss WA; Yang X; Haas-Kogan DA; Matthay KK; Seo Y
Med Phys; 2010 Sep; 37(9):4861-7. PubMed ID: 20964203
[TBL] [Abstract][Full Text] [Related]
13. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
[TBL] [Abstract][Full Text] [Related]
14. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG).
Fitzgerald PA; Goldsby RE; Huberty JP; Price DC; Hawkins RA; Veatch JJ; Dela Cruz F; Jahan TM; Linker CA; Damon L; Matthay KK
Ann N Y Acad Sci; 2006 Aug; 1073():465-90. PubMed ID: 17102115
[TBL] [Abstract][Full Text] [Related]
15. [Salivary gland damage after 131I therapy in patients with differentiated thyroid cancer. Preliminary report].
Macioszek A; Baczyk M; Kopeć T; Sowiński J
Endokrynol Pol; 2008; 59(5):403-10. PubMed ID: 18979451
[TBL] [Abstract][Full Text] [Related]
16. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
[TBL] [Abstract][Full Text] [Related]
17. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial.
Liu B; Kuang A; Huang R; Zhao Z; Zeng Y; Wang J; Tian R
J Nucl Med; 2010 Apr; 51(4):618-23. PubMed ID: 20237029
[TBL] [Abstract][Full Text] [Related]
18. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
[TBL] [Abstract][Full Text] [Related]
19. Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine.
Bohuslavizki KH; Brenner W; Lassmann S; Tinnemeyer S; Tönshoff G; Sippel C; Wolf H; Clausen M; Henze E
Nucl Med Commun; 1996 Aug; 17(8):681-6. PubMed ID: 8878127
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of
Maric I; Weber M; Prochnow A; Schmitz J; Unger N; Schaarschmidt BM; Poeppel TD; Rischpler C; Bockisch A; Herrmann K; Jentzen W; Fendler WP
J Nucl Med; 2023 Jun; 64(6):885-891. PubMed ID: 36732054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]